Latest News

Stay up-to-date on the latest developments in the fields of vitreo-retinal disease treatments and ophthalmology in general. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with ThromboGenics associates. Be sure to check in regularly for the latest ThromboGenics’ press releases or just subscribe to our mailing list to receive regular updates.

Haven’t found what you’re looking for? Take a look at our press release history.



  • 16 Aug 2017
    New Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 in Boston
  • 10 Jul 2017
    ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement
  • 15 Jun 2017
    Thomas Clay Appointed Chairman of the Board of Directors
  • 8 Jun 2017
    ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress
  • 24 May 2017
    ThromboGenics to present THR-317 Pre-clinical Research Findings at the EASDec Meeting
  • 11 May 2017
    ThromboGenics Business Update – Q1 2017
  • 2 May 2017
    New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore
  • 26 Apr 2017
    Regulated Information - Transparency Statement
  • 20 Apr 2017
    ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema
  • 16 Mar 2017
    ThromboGenics Business Update – FY 2016
  • 29 Jan 2017
    Regulated Information - Transparency Statement
  • 17 Jan 2017
    ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma
  • 10 Jan 2017
    ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME)
  • 23 Dec 2016
    ThromboGenics Announces Protocol Amendment to Phase II CIRCLE Trial Evaluating THR-409 (ocriplasmin) in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)
  • 9 Dec 2016
    ThromboGenics Announces Financial Calendar 2017